Rudolf A. de Boer

82.7k total citations · 11 hit papers
559 papers, 22.3k citations indexed

About

Rudolf A. de Boer is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Rudolf A. de Boer has authored 559 papers receiving a total of 22.3k indexed citations (citations by other indexed papers that have themselves been cited), including 349 papers in Cardiology and Cardiovascular Medicine, 120 papers in Molecular Biology and 97 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Rudolf A. de Boer's work include Heart Failure Treatment and Management (161 papers), Cardiovascular Function and Risk Factors (143 papers) and Diabetes Treatment and Management (75 papers). Rudolf A. de Boer is often cited by papers focused on Heart Failure Treatment and Management (161 papers), Cardiovascular Function and Risk Factors (143 papers) and Diabetes Treatment and Management (75 papers). Rudolf A. de Boer collaborates with scholars based in Netherlands, United States and United Kingdom. Rudolf A. de Boer's co-authors include Dirk J. van Veldhuisen, Wiek H. van Gilst, Herman H.W. Silljé, Adriaan A. Voors, Wouter C. Meijers, Pim van der Harst, Peter van der Meer, Hans L. Hillege, B. Daan Westenbrink and Navin Suthahar and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Circulation.

In The Last Decade

Rudolf A. de Boer

530 papers receiving 21.8k citations

Hit Papers

SGLT2 inhibitors in patie... 2013 2026 2017 2021 2022 2019 2013 2017 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
    2022 491 citations Rudolf A. de Boer et al. profile →
  2. Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations
    2019 464 citations Christian Mueller, Rudolf A. de Boer et al. European Journal of Heart Failure profile →
  3. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND
    2013 423 citations Rudolf A. de Boer, Pim van der Harst et al. profile →
  4. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association
    2017 404 citations Sheryl L. Chow, Alan S. Maisel et al. Circulation profile →
  5. Iron Deficiency Impairs Contractility of Human Cardiomyocytes Through Decreased Mitochondrial Function
    2018 255 citations Martijn F. Hoes, Niels Grote Beverborg et al. European Journal of Heart Failure profile →
  6. Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction
    2019 248 citations Salva R. Yurista, Herman H.W. Silljé et al. European Journal of Heart Failure profile →
  7. Heart Failure Stimulates Tumor Growth by Circulating Factors
    2018 241 citations Wouter C. Meijers, Stephan J. L. Bakker et al. Circulation profile →
  8. Heart failure with preserved ejection fraction: from mechanisms to therapies
    2018 230 citations Adriaan A. Voors, Rudolf A. de Boer et al. profile →
  9. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
    2021 182 citations Rudolf A. de Boer et al. European Journal of Heart Failure profile →
  10. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis
    2022 146 citations Rudolf A. de Boer, Michiel Rienstra et al. profile →
  11. Telemonitoring for heart failure: a meta-analysis
    2023 72 citations Eric Boersma, Rudolf A. de Boer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rudolf A. de Boer Netherlands 79 11.3k 5.3k 3.7k 3.3k 3.2k 559 22.3k
Johann Bauersachs Germany 88 10.9k 1.0× 8.0k 1.5× 2.2k 0.6× 5.3k 1.6× 3.1k 1.0× 577 24.6k
Dimitris Tousoulis Greece 68 9.1k 0.8× 3.8k 0.7× 2.3k 0.6× 3.9k 1.2× 2.2k 0.7× 811 20.5k
Arshed A. Quyyumi United States 86 14.8k 1.3× 5.0k 1.0× 2.3k 0.6× 5.5k 1.6× 3.5k 1.1× 484 29.7k
Ton J. Rabelink Netherlands 81 6.9k 0.6× 7.1k 1.3× 2.5k 0.7× 4.9k 1.5× 3.5k 1.1× 542 25.9k
Javier Dı́ez Spain 76 12.0k 1.1× 4.7k 0.9× 1.5k 0.4× 3.2k 1.0× 2.2k 0.7× 407 19.8k
Tsutomu Imaizumi Japan 76 7.3k 0.6× 6.8k 1.3× 1.9k 0.5× 4.8k 1.4× 2.7k 0.8× 350 21.1k
Keith M. Channon United Kingdom 83 8.4k 0.7× 6.0k 1.1× 3.4k 0.9× 4.8k 1.4× 1.5k 0.5× 493 23.2k
Aroon D. Hingorani United Kingdom 72 7.0k 0.6× 3.6k 0.7× 1.9k 0.5× 4.5k 1.3× 3.3k 1.0× 266 26.0k
Hiroyuki Tsutsui Japan 75 11.7k 1.0× 7.1k 1.3× 1.8k 0.5× 2.8k 0.8× 1.4k 0.4× 645 22.4k
Helmut Drexler Germany 79 15.2k 1.3× 6.9k 1.3× 3.3k 0.9× 6.5k 1.9× 2.4k 0.7× 176 29.8k

Countries citing papers authored by Rudolf A. de Boer

Since Specialization
Citations

This map shows the geographic impact of Rudolf A. de Boer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rudolf A. de Boer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rudolf A. de Boer more than expected).

Fields of papers citing papers by Rudolf A. de Boer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rudolf A. de Boer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rudolf A. de Boer. The network helps show where Rudolf A. de Boer may publish in the future.

Co-authorship network of co-authors of Rudolf A. de Boer

This figure shows the co-authorship network connecting the top 25 collaborators of Rudolf A. de Boer. A scholar is included among the top collaborators of Rudolf A. de Boer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rudolf A. de Boer. Rudolf A. de Boer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zwetsloot, Peter-Paul, Alexander Hirsch, Arend F. L. Schinkel, et al.. (2025). Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy. Heart. 112(6). 333–340.
2.
Cox, Moniek G.P.J., Tom E. Verstraelen, Remco de Brouwer, et al.. (2025). The role of comorbidities and lifestyle factors in disease progression of phospholamban cardiomyopathy. European Journal of Preventive Cardiology. 33(2). 297–300. 1 indexed citations
3.
Aboumsallem, Joseph Pierre, et al.. (2024). Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions. European Journal of Pharmacology. 985. 177110–177110. 1 indexed citations
4.
Schinkel, Arend F. L., Alexander Hirsch, Peter-Paul Zwetsloot, et al.. (2024). Family screening for hypertrophic cardiomyopathy: Initial cardiologic assessment, and long-term follow-up of genotype-positive phenotype-negative individuals. International Journal of Cardiology. 422. 132951–132951. 2 indexed citations
5.
Shakoor, Abdul, Jeroen Schaap, Rudolf A. de Boer, et al.. (2024). Socio-Economic Inequalities and Heart Failure Morbidity and Mortality: A Systematic Review and Data Synthesis. ESC Heart Failure. 12(2). 927–941. 3 indexed citations
6.
Jansen, M., Remco de Brouwer, Amand F. Schmidt, et al.. (2023). Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies. JACC Heart Failure. 12(1). 134–147. 9 indexed citations
7.
Eijgenraam, Tim R., Elisabeth M. Schouten, Diederik W.D. Kuster, et al.. (2023). DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters. Circulation Research. 133(12). 1006–1021. 18 indexed citations
8.
Markousis‐Mavrogenis, George, Waldemar B. Minich, Stefan D. Anker, et al.. (2023). Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. Cardiovascular Research. 119(8). 1690–1705. 2 indexed citations
9.
Beverborg, Niels Grote, Martin H. de Borst, Ron T. Gansevoort, et al.. (2023). Micronutrient deficiencies and new-onset atrial fibrillation in a community-based cohort: data from PREVEND. Clinical Research in Cardiology. 114(1). 41–52. 11 indexed citations
10.
Yurista, Salva R., et al.. (2022). SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis. 11(1). 1–1. 55 indexed citations
11.
Jansen, M., Imke Christiaans, Saskia N. van der Crabben, et al.. (2021). BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status. Netherlands Heart Journal. 29(6). 318–329. 6 indexed citations
12.
Suthahar, Navin, Laura M G Meems, Dirk J. van Veldhuisen, et al.. (2020). High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. Mayo Clinic Proceedings. 95(6). 1158–1168. 11 indexed citations
13.
Tini, Giacomo, Edoardo Bertero, Alessio Signori, et al.. (2020). Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 9(18). e016309–e016309. 27 indexed citations
14.
Pol, Atze van der, Martijn F. Hoes, Rudolf A. de Boer, & Peter van der Meer. (2020). Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. Journal of Internal Medicine. 288(5). 491–506. 15 indexed citations
15.
Chow, Sheryl L., Alan S. Maisel, Inder S. Anand, et al.. (2017). Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 135(22). e1054–e1091. 404 indexed citations breakdown →
16.
Haehling, Stephan von, Dirk J. van Veldhuisen, Sy Ha, et al.. (2011). Anaemia Among Patients with Heart Failure and Preserved or Reduced Ejection Fraction: Results from the SENIORS Study. European Journal of Heart Failure. 13(6). 656–663. 50 indexed citations
17.
Li, Jiang, Inge Vreeswijk‐Baudoin, Pim van der Harst, et al.. (2010). Activation of Liver X Receptors with T0901317 Attenuates Cardiac Hypertrophy in vivo. European Journal of Heart Failure. 12(10). 1042–1050. 33 indexed citations
18.
Backlund, Michael, Kirsi Paukku, Laurent Daviet, et al.. (2009). Posttranscriptional regulation of angiotensin II type 1 receptor expression by glyceraldehyde 3-phosphate dehydrogenase. Nucleic Acids Research. 37(7). 2346–2358. 42 indexed citations
19.
Hillege, Hans, et al.. (2008). BNP and NT-proBNP, Predictors of 1-Year Mortality in Nursing Home Residents. Journal of the American Medical Directors Association. 9(8). 580–585. 14 indexed citations
20.
Meer, Peter van der, Erik Lipšic, Robert H. Henning, et al.. (2004). Erythropoietin Improves Left Ventricular Function and Coronary Flow in an Experimental Model of Ischemia-Reperfusion Injury. European Journal of Heart Failure. 6(7). 853–859. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johann Bauersachs Breakdown of academic impact, for papers by Dimitris Tousoulis Breakdown of academic impact, for papers by Arshed A. Quyyumi Breakdown of academic impact, for papers by Ton J. Rabelink Breakdown of academic impact, for papers by Javier Dı́ez Breakdown of academic impact, for papers by Tsutomu Imaizumi Breakdown of academic impact, for papers by Keith M. Channon Breakdown of academic impact, for papers by Aroon D. Hingorani Breakdown of academic impact, for papers by Hiroyuki Tsutsui Breakdown of academic impact, for papers by Helmut Drexler
Rankless by CCL
2026